The November 2026 Editors’ Picks from AACR journals include a potential strategy to make immune checkpoint inhibitors less toxic without compromising their effectiveness; how an HDAC inhibitor can sensitize metastatic breast cancer to dual checkpoint inhibition; two phase II trials of neoadjuvant chemoimmunotherapy; and more. The post Editors’ Picks, November 2026: Less Toxic Immunotherapy, Targeting the Breast Cancer Microenvironment, Clinical Trials, and More appeared first on American Association for Cancer Research (AACR) .
https://www.aacr.org/blog/2026/11/20/editors-picks-november-2026-less-toxic-immunotherapy-targeting-the-breast-cancer-microenvironment-clinical-trials-and-more/